Xenon, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst David Martin PhD from Bloom Burton maintained a Buy rating on the stock and has a $56.50 price target.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
David Martin PhD has given his Buy rating due to a combination of factors including the promising developments in Xenon Pharmaceuticals’ early-stage pipeline. The company recently hosted an investor webinar that highlighted their focus on innovative non-opioid pain treatments targeting Kv7 and Nav1.7 channels, specifically through their XEN1120 and XEN1701 programs.
Both programs have shown significant potential, with strong efficacy and safety results in preclinical testing. Additionally, XEN1701 benefits from robust genetic validation. These advancements suggest that Xenon’s lead candidates could effectively address the limitations of previous treatments, which supports the positive outlook on the company’s stock.
In another report released yesterday, Chardan Capital also reiterated a Buy rating on the stock with a $55.00 price target.